The rHuPH20 Enzyme
WASHINGTON /PRNewswire-FirstCall/ — Halozyme Therapeutics, Inc. a development stage biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, announced that results from new preclinical studies with Halozyme’s recombinant human PH20 (rHuPH20) hyaluronidase enzyme were presented at the 2005 American Society of Cataract & Refractive Surgery (ASCRS) Symposium on Cataract, IOL and Refractive […]